Company Information


Dublin, Ireland


Corey Fishman


Arix Representative

Among the most important demands were new treatments for common, often serious conditions, including urinary tract infections (UTI), and intra-abdominal infections (IAI). Increasingly, these are caused by pathogens that have evolved resistance to today's antibiotics.

Iterum Therapeutics plc (NASDAQ: ITRM) is a late clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product, sulopenem, is the first oral and IV penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative infections in both the hospital and community settings. Iterum has received QIDP designations for its oral and IV formulations for the treatment of uncomplicated urinary tract infections (uUTI), complicated urinary tract infections (cUTI) and complicated intra abdominal infections (cIAI).

The Company is led by industry veterans Corey Fishman, Chief Executive Officer and Michael Dunne, MD, Chief Scientific Officer. Prior to founding Iterum Therapeutics, Mr. Fishman served as CFO and COO of Durata Therapeutics. Inc. where he raised over $225M in capital and led the negotiation and sale of the company to Actavis plc in 2014. Dr. Dunne worked with Mr. Fishman at Durata Therapeutics as Chief Medical Officer, where he successfully led all development efforts for dalbavancin through FDA & EMA approval.